Vascular Biogenics Ltd (NASDAQ:VBLT)

0.1652
Delayed Data
As of Feb 02
 +0.0008 / +0.48%
Today’s Change
0.10
Today|||52-Week Range
2.20
+37.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$10.4M

Company Description

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Contact Information

Vascular Biogenics Ltd.
8 HaSatat Street
Modi’in Jerusalem 7178106
P:(728) 993-5000
Investor Relations:

Employees

Shareholders

Individual stakeholders8.79%
Other institutional4.79%
Mutual fund holders0.08%

Top Executives

Dror HaratsChief Executive Officer & Director
Eyal BreitbartSenior Vice President-Research & Operations
Erez FeigeSenior Vice President-Business Operations
Samuel I. BackenrothChief Financial Officer
Tami RachmilewitzSenior Vice President-Clinical Development